Recent advances in neuroblastoma.

Area of Science:

• Pediatric Oncology
• Surgical Oncology
• Translational Cancer Research

Background:

• Neuroblastoma treatment remains a significant clinical challenge, with stagnant 5-year survival rates despite multimodal therapy advancements.
• Identification of genetic features has not yet translated into substantial survival gains for neuroblastoma patients.
• Current research focuses on novel therapeutic targets and refined surgical strategies to improve outcomes.

Purpose of the Study:

• To review current operative strategies for neuroblastoma treatment.
• To highlight recent research developments aimed at improving neuroblastoma survival rates.
• To discuss the potential of new therapeutic targets in managing advanced-stage neuroblastoma.

Main Methods:

• Review of current literature on neuroblastoma surgical interventions.
• Analysis of recent research findings in neuroblastoma targeted therapies.
• Discussion of emerging treatment modalities including tyrosine kinase inhibition, differentiation agents, pathway inhibitors, and immunotherapy.

Main Results:

• Complete curative resection is the primary goal in early-stage neuroblastoma; tissue biopsy is crucial for staging in advanced disease.
• Minimally invasive surgery (MIS) is increasingly considered for select neuroblastoma patients.
• Promising preclinical results have been observed with novel agents targeting tyrosine kinases, differentiation pathways, and immunotherapy.

Conclusions:

• Understanding cell signaling and targeting specific genes are crucial for advancing neuroblastoma treatment.
• Novel treatment strategies derived from ongoing research are essential for improving survival in advanced-stage neuroblastoma.
• Continued research into targeted therapies and surgical techniques is vital for overcoming the challenges in neuroblastoma management.